Patients demographics
| Amantadine group (n = 85) | Placebo group (n = 86) | p Value | |
|---|---|---|---|
| ALT, alanine aminotransferase; TSH, thyroid stimulating hormone; PT, prothrombin time; WBC, white blood count; HCV, hepatitis C virus; PCR, polymerase chain reaction. | |||
| Results are mean (SD) unless otherwise indicated. | |||
| Age (y) | 44.6 (6.9) | 43.9 (7.0) | 0.5 |
| <50 y | 82.4% (n = 70) | 75.6% (n = 65) | 0.2 |
| >50 y | 17.6% (n = 15) | 24.4% (n = 21) | |
| Genotype | |||
| 1a/b | 87.1% (n = 74) | 82.6% (n = 71) | 0.3 |
| 2, 3 | 10.6% (n = 9) | 15.1% (n = 13) | 0.3 |
| 4, 5 | 0 | 0 | |
| Unable to genotype | 2.4%(n = 2) | 2.3% (n = 2) | |
| Race | 0.5 | ||
| Caucasian | 78.8% (n = 67) | 83.7% (n = 72) | |
| African-American | 20% (n = 17) | 14% (n = 12) | |
| Other | 1.2% (n = 1) | 2.3% (n = 2) | |
| Sex (male) | 52.9% (n = 45) | 61.6% (n = 55) | 0.2 |
| Severity of fibrosis | 0.2 | ||
| Cirrhosis/septate fibrosis | 18.8% (n = 16) | 25.6% (n = 22) | |
| Minimal/no fibrosis | 81.2% (n = 69) | 74.4% (n = 64) | |
| Baseline laboratory results | |||
| ALT | 103 (126) | 90 (66) | 0.4 |
| TSH | 1.88 (1.2) | 1.93 (1.2) | 0.9 |
| Albumin (mg/dl) | 4.2 (0.4) | 4.1 (0.4) | 0.3 |
| Bilirubin (mg/dl) | 0.68 (0.4) | 0.74 (0.5) | 0.4 |
| Haemoglobin (g/dl) | 14.6 (1.4) | 14.8 (1.2) | 0.3 |
| WBC count/mm3 | 6482 (1985) | 6946 (4479) | 0.4 |
| Platelet count/mm3 | 201 (71) | 188 (64) | 0.2 |
| Creatinine (mg/dl) | 0.92 (0.2) | 0.87 (0.2) | 0.1 |
| PT (s) | 12 (2.5) | 11.7 (1.5) | 0.5 |
| HCV RNA level by PCR | 0.4 | ||
| <1 000 000 copies/ml | 60% (n = 51) | 57% (n = 49) | |
| >1 000 000 copies/ml | 40% (n = 34) | 43% (n = 37) | |